A first-in-human, open-label, clinical study to assess the safety, tolerability, and activity of OT-C001 (amplified/activated allogenic natural killer cells) in patients with relapsed/refractory diffuse large B-cell lymphoma

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 10
• 2 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose diffuse large B-cell lymphoma has come back or has not responded to treatment. It tests the safety and activity of OT-C001, a natural killer cell therapy.

Age

18 years or older

Sex

All sexes can join

Disease stage

Diffuse large B-cell lymphoma that has relapsed (come back) or is refractory (did not respond to treatment)

Main reasons for not taking part

• Healthy volunteers cannot join

Read by machine on 9 Nov 2026.

Sites (2)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details